Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma

Journal of Immunotherapy

Volumn 21, Issue 3, 1998, Pages 170-180

  Mulders, Peter ^a   Tso, Cho Lea ^a   Pang, Shen ^a   Kaboo, Randhir ^a   McBride, William H ^a   Hinkel, Andreas ^a   Gitlitz, Barbara ^a   Dannull, Jens ^a   Figlin, Robert ^a   Belldegrun, Arie ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adenovirus; Gene therapy; Interleukin 2 (IL 2); Renal cell carcinoma (RCC); Tumor infiltrating lymphocytes (TILs)

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 6; MESSENGER RNA; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE;

ADENOVIRUS; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; FLUORESCENCE ACTIVATED CELL SORTER; GENE TRANSFER; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LYMPHOKINE ACTIVATED KILLER CELL; NATURAL KILLER CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0031923676     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199805000-00002     Document Type: Article

References (42)

1. Belldegrun A, Pierce W, Kaboo R, et al. Interferon alpha-primed tumor infiltrating lymphocytes combined with interleukin 2 and interferon-alpha as a therapy for metastatic renal cell carcinoma. J Urol 1993;150:1384-90.
2. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J 1996;65:5-27.
3. SEER Cancer statistics review 1973-1990. National Institutes of Health Publication A 93:2789. Bethesda, MD: National Institutes of Health, 1993.
4. Belldegrun A, Abi-Aad A, Figlin RA. Renal cell carcinoma: basic biology and current approaches to therapy. Semin Oncol 1992;18:96-101.
5. Fyfe GA, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Long term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy [Letter]. J Clin Oncol 1996;14:2410-1.
6. Taneja SS, Pierce W, Figlin R, Belldegrun A. Immunotherapy for renal cell carcinoma: the era of interleukin-2-based treatment. Urology 1995;45:911-24.
7. Whittington R, Faulds D. Interleukin-2: review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 1993;46:446-514.
8. Figlin RA, Pierce WC, Kaboo R, et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol 1997;158:740-5.
9. Mizoguchi H, O’Shea JJ, Ochoa AC, et al. Alternations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992;258:1795-8.
10. lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1994;53:5613-6.
11. Belldegrun A, Muul LM, Rosenberg SA. Interleukin-2 expanded tumor infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and anti-tumor activity. Cancer Res 1988;48:206-14.
12. Wang Q, Redovan C, Tubbs, et al. Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor infiltrating lymphocytes. Int J Cancer 1995;61:780-5.
13. Belldegrun A, Tso CL, Kaboo R, et al. Natural immune reactivityassociated therapeutic response in patients with metastatic renal cell carcinoma (RCC) receiving tumor-infiltrating lymphocytes (TILs) and interleukin-2 (IL-2) based therapy. J Immunother 1996;19:149-61.
14. Dilloo D, Bacon K, Holden W, et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nature Med 1996;10:1090-5.
15. Zier KS, Gansbacher B. IL-2 gene therapy of solid tumors: an approach for the prevention of signal transduction defects in T cells. J Mol Med 1996;74:127-34.
16. Mahvi DM, Burkholder JK, Turner J, et al. Particle-mediated gene transfer of granulocyte-macrophage colony-stimulating factor cDNA to tumor cells: implications for a clinically relevant tumor vaccine. Hum Gene Ther 1996;7:1535-43.
17. Hurford RK Jr, Dranoff G, Mulligan RC, Tepper RI. Gene therapy of metastatic cancer by in vivo retroviral gene targeting. Nature Genet 1995;10:430-5.
18. + T cell-dependent tumor rejection. J Exp Med 1991;174:1291-8.
19. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-6.
20. Progador A, Tzehoval E, Katz A, et al. IL-6 gene transfection into 3 LL tumor cells suppress the malignant phenotype and confers immuno-therapeutic competent against parental metastatic cells. Cancer Res 1992;52:3679-86.
21. Blankenstein T, Qin Z, Uberla K, et al. Tumor suppression after cell-targeted tumor necrosis factor: a gene transfer. J Exp Med 1991;173:1047-52.
22. Vieweg J, Boczkowski D, Roberson KM, et al. Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res 1996;55:2366-72.
23. Abe J, Wakimoto H, Tsunoda R, et al. In vivo antitumor effect of cytotoxic T lymphocytes engineered to produce interferon-gamma by adenovirus-mediated genetic transduction. Biochem Biophys Res Commun 1996;5(218):164-70.
24. Berkner KL. Development of adenovirus vectors for the expression of heterologous genes. Biotechniques 1988;6:616-29.
25. Crystal RG, McEivaney NG, Rosenfeld MA, et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nature Genet 1994;8:42-51.
26. + T cells against autologous tumor cells. Jpn J Cancer Res 1995;86:854-60.
27. Whiteside TL, Miescher S, von Fliedner V, et al. Cloning and proliferating precursor frequencies of tumor-infiltrating lymphocytes from human solid tumors. Transplant Proc 1998;20:342-3.
28. Applegate KG, Balch CM, Pellis NR. In vitro migration of lymphocytes through collagen matrix: arrested locomotion in TILs. Cancer Res 1990;50:7153-8.
29. + T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with combinant vaccinia virus. J Immunol 1996;157:4079-86.
30. + cytotoxic T lymphocytes stimulated by immobilized anti-CD3 monoclonal antibody and interleukin-2 in cancer patients. Int J Cancer 1995;60:802-7.
31. Gabrilovich DI, Ciernik IF, Carbone DP. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol 1996;170:101-10.
32. Belldegrun A, Tso C-L, Sakata S, et al. Human renal carcinoma line transfected with interleukin-2 and/or interferon-a gene(s): Implications for live cancer vaccine. J Natl Cancer Inst 1993:85:207-16.
33. Fearon ER, Pardoll DM, Frost P, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;60:397-403.
34. Gansbacher B, Zier K, Daniels B, et al. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990;172:1217-24.
35. Koo AS, Tso CL, Shimabukuro T, Peyret C, deKernion JB, Belldegrun A. Autologous tumor-specific cytotoxicity of tumor infiltrating lymphocytes derived from human renal cell carcinoma. J Immunother 1991;10:347-54.
36. 2-restricted recognition of autologous and allogenic tumor line. J Immunol 1993;151:4209-20.
37. Yang Y, Trinchieri G, Wilson JM, et al. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Med 1995;1:890-3.
38. Fang B, Eisensmith RC, Wang H, et al. Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther 1995;6:1039-44.
39. Schwartzentruber DJ, Topalian SL, Rosenberg SA, et al. Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-a and IFN-7 by human tumor infiltrating lymphocytes after autologous tumor stimulation. J Immunol 1991;146:3674-81.
40. Schwartzentruber DJ, Horn SS, Dadmar ZR, et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor infiltrating lymphocytes and interleukin-2. J Clin Oncol 1994;12:1475-83.
41. Aebersold P, Hyatt C, Johnson S, et al. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. J Natl Cancer Inst 1991;83:932-7.
42. Cao X, Zhang W, Gu S, Yu Y, Tao Q, Ye T. Induction of antitumor immunity and treatment of preestablished tumor by interleukin-6gene-transfected melanoma cells combined with low-dose interleukin-2. J Cancer Res Clin Oncol 1995;121:721-8.